Factors affecting the clinical outcome of pediatric Anti- N-Methyl-Daspartate receptor encephalitis, a single center study.
- Author:
Melady D. Imperial-Gilbuena
;
Rose Daynielle A. Cansanay
;
Madelyn P. Pascual
;
Mel Michel G. Villaluz
;
Marilyn H. Ortiz
;
Lillian V. Lee
- Publication Type:Journal Article
- Keywords:
Anti-NMDAR Encephalitis;
Autoimmune
- From:
The Philippine Children’s Medical Center Journal
2022;18(2):63-89
- CountryPhilippines
- Language:English
-
Abstract:
BACKGROUND:Anti-N-Methyl-D-Aspartate receptor (anti-NMDAR) Encephalitis is the most common type of autoimmune encephalitis that affects children, adolescents and young adults. Since its discovery in 2007, there is still a paucity of data on the disease and factors affecting its outcome.
OBJECTIVES:To describe the clinical characteristics of children and adolescents with anti-NMDAR
encephalitis and to analyze factors that may affect its outcome.
METHODS:Forty-three patient records of diagnosed anti-NMDAR Encephalitis were included. The outcome was evaluated using the modified Rankin Scale (mRS), and Clinical Assessment Scale for autoimmune Encephalitis (CASE).
RESULTS:Ages ranged from 2 years to 18 years old, majority in the 12-18 years age range. Sixty percent were female. First line treatment using immunotherapy was given to all patients: 37% as monotherapy and 84% combination therapy (MPT only 23%, IVIg only 4%, MPT + IVIg or TPE 21-26%, and MPT + IVIg + TPE 16%). Clinical outcomes on discharge and on follow-up were assessed using the mRS and CASE. On discharge the proportion of the patients who had mild impairment (mRS<2, CASE<9) was more than 50%. On median duration follow-up of 31 weeks (range 24-40 weeks), 96.8% had significant improvement (mRS<2, CASE<9). Among the possible factors that were assessed to affect outcome, only severity of the illness at the start of the treatment influenced clinical outcome.
CONCLUSION:Early diagnosis and initiation of treatment before the progression of the disease will promote faster recovery and more optimal clinical outcome. CASE may be used as an additional tool in assessing response to treatment.
- Full text:Factors affecting the clinical.pdf
